AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Burnout among physicians and residents continues to grow, with six out of 10 reporting these feelings, along with continued ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

Because of having a compromised immune system from cancer with chemotherapy along with asthma, I didn’t venture out during the COVID pandemic.

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the ...

Appendectomies are not benign. They can compromise a healthy gut and raise the risk of psychiatric disorders. Fortunately, there are alternatives.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

RFK Jr. is a high-profile face of vaccine hesitancy, but people's vaccine concerns fall on a much broader spectrum.